FeesSafety
Pluang+

Cue Biopharma reports strong Phase 2 results for CUE-221 in chronic urticaria and starts Phase 1 trial for CUE-401 autoimmune drug

Company Fundamentals
16 Nov 2026, 23:48 WIB
GlobeNewsWire
View Source
Bullish
Cue Biopharma reports strong Phase 2 results for CUE-221 in chronic urticaria and starts Phase 1 trial for CUE-401 autoimmune drug

Cue Biopharma announced positive Phase 2 results for its CUE-221 drug in treating chronic spontaneous urticaria (CSU), showing significant clinical benefits and potential to help more patients, including those with high IgE levels. The company also initiated the first-in-human Phase 1 trial for CUE-401, a novel autoimmune therapy designed to regulate inflammation and restore immune tolerance. Financially, Cue reported a net loss of $50 million in Q3 2026, reflecting increased clinical development expenses, but holds $57.9 million in cash. The FDA has cleared CUE-221 for food allergy trials, supporting further clinical advancement. These developments position Cue Biopharma to expand its portfolio targeting allergic and autoimmune diseases.

Cue Biopharma's recent financial and clinical updates provide context for readers following health-related biotech developments. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 17, 2026 04:12 WIB: out of 150 priced US health-sector stocks tradable on Pluang, 29 rose and 121 fell today. Notable movers include NUWE at USD 4.51 down 7.96%, HRTX at USD 0.29 down 7.54% with balanced Pluang order activity, and ARWR at USD 44.21 down 7.47%.

More News

Agora reports 19% revenue growth in Q3 2026 with rising AI adoption and positive net income

Agora reports 19% revenue growth in Q3 2026 with rising AI adoption and positive net income

Agora, Inc. announced a 19% increase in revenue to $42.1 million for Q3 2026, driven by growth in real-time engagement and conversational AI products. The company reported net income of $3.0 million and maintained GAAP profitability for the eighth co...

Company Fundamentals
Bullish
59 minutes ago
Vietnam plastics market to reach 20.47 million tons by 2032, driven by construction and packaging growth.

Vietnam plastics market to reach 20.47 million tons by 2032, driven by construction and packaging growth.

The Vietnam plastics market is projected to grow at a CAGR of 8.05% from 2027 to 2032, increasing from 13.9 million tons in 2027 to 20.47 million tons by 2032. Growth is fueled by expanding construction activities, rising demand for food-grade and e-...

Market News
Bullish
59 minutes ago
58% of Latin American mining execs favor democratic nation investment despite infrastructure gaps

58% of Latin American mining execs favor democratic nation investment despite infrastructure gaps

A survey of Latin American mining executives reveals 58% support prioritizing investment from democratic countries for critical minerals, even at some economic cost. However, only 21% believe their countries have adequate infrastructure, and just one...

Market News
Neutral
1 hour ago
Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney's fiscal Q4 report, due November 17, is expected to show strong growth with analysts forecasting over 50% earnings per share (EPS) growth and more than 12% revenue increase. Streaming revenue rose 11% last quarter with margins hitting double d...

Company Fundamentals
Bullish
3 hours ago
Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox has launched a new Australia realm on Amazon Web Services (AWS) in the Sydney region, providing Australian government agencies and enterprises a local option for managing DNS, DHCP, and IP address management (DDI) with enhanced security. Thi...

Market News
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App